{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:10:57Z","timestamp":1790874657005,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Acute kidney injury (AKI), a rapid decrease in kidney function, is associated with increased risk of adverse outcomes including development and progression of CKD. Kidney fibrosis is one of the pathological processes central to this AKI-to-CKD transition. Here we investigate the association of biomarkers of collagen type III turnover with adverse outcome following AKI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We measured three biomarkers reflecting collagen type III (PRO-C3) formation and degradation (C3M and C3C) in plasma samples collected 1 year after an episode of AKI in 800 patients (392 patients with AKI and 408 non-AKI controls) from the prospective AKI Risk in Derby (ARID) study. Patients were followed until 3 years after the episode of AKI and the following outcomes were assessed: kidney disease progression, mortality, heart failure, cardiovascular events, and hospital readmission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PRO-C3 levels were elevated in the AKI group compared with the controls (P\u00a0&amp;lt;\u00a0.001), whereas C3M and C3C levels were not different between groups. In multivariate models including common risk factors, PRO-C3 was prognostic for kidney disease progression and mortality in the AKI group and for heart failure in the control group. C3M and C3C were not prognostic for any of the investigated outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Circulating PRO-C3, a biomarker of fibroblast activity, was prognostic for kidney disease progression and mortality when measured 1 year after an episode of AKI. Biomarkers of fibroblast activity may help patient stratification after an episode of AKI by identifying patients at higher risk of kidney disease progression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae413","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T02:49:49Z","timestamp":1734576589000},"source":"Crossref","is-referenced-by-count":3,"title":["Collagen type III formation but not degradation is associated with risk of kidney disease progression and mortality after acute kidney injury"],"prefix":"10.1093","volume":"18","author":[{"given":"Nadja","family":"Sparding","sequence":"first","affiliation":[{"name":"Cardiovascular and Renal Research, Nordic Bioscience , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-1881","authenticated-orcid":false,"given":"Federica","family":"Genovese","sequence":"additional","affiliation":[{"name":"Cardiovascular and Renal Research, Nordic Bioscience , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-8740","authenticated-orcid":false,"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[{"name":"Cardiovascular and Renal Research, Nordic Bioscience , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-8326","authenticated-orcid":false,"given":"Nicholas M","family":"Selby","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, University of Nottingham , Nottingham ,","place":["UK"]},{"name":"Department of Renal Medicine, University Hospitals of Derby and Burton , Derby ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"2025022408425833600_bib1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025022408425833600_bib2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.kint.2018.08.036","article-title":"Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure","volume":"95","author":"See","year":"2019","journal-title":"Kidney Int"},{"key":"2025022408425833600_bib3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2215\/CJN.10410919","article-title":"Long-term outcomes in patients with acute kidney injury","volume":"15","author":"Noble","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025022408425833600_bib4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/ki.2011.379","article-title":"Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis","volume":"81","author":"Coca","year":"2012","journal-title":"Kidney Int"},{"key":"2025022408425833600_bib5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2016-015316","article-title":"Three-year outcomes after acute kidney injury: results of a prospective parallel group cohort study","volume":"7","author":"Horne","year":"2017","journal-title":"BMJ Open"},{"key":"2025022408425833600_bib6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/ndt\/gfz155","article-title":"Recurrent acute kidney injury: predictors and impact in a large population-based cohort","volume":"35","author":"Holmes","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025022408425833600_bib7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000497385","article-title":"Predicting risk of recurrent acute kidney injury: a systematic review","volume":"142","author":"Hounkpatin","year":"2019","journal-title":"Nephron"},{"key":"2025022408425833600_bib8","doi-asserted-by":"publisher","first-page":"e0219828","DOI":"10.1371\/journal.pone.0219828","article-title":"The influence of multiple episodes of acute kidney injury on survival and progression to end stage kidney disease in patients with chronic kidney disease","volume":"14","author":"Sykes","year":"2019","journal-title":"PLoS One"},{"key":"2025022408425833600_bib9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1681\/ASN.2016010105","article-title":"AKI and long-term risk for cardiovascular events and mortality","volume":"28","author":"Odutayo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025022408425833600_bib10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.7326\/M22-3617","article-title":"Risk for chronic kidney disease progression after acute kidney injury: findings from the chronic renal insufficiency cohort study","volume":"176","author":"Muiru","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025022408425833600_bib11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.34067\/KID.0000422021","article-title":"Circulating levels of endotrophin are prognostic for long-term mortality after AKI","volume":"3","author":"Sparding","year":"2022","journal-title":"Kidney360"},{"key":"2025022408425833600_bib12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/biom13071093","article-title":"Unique biomarkers of collagen type III remodeling reflect different information regarding pathological kidney tissue alterations in patients with IgA nephropathy","volume":"13","author":"Sparding","year":"2023","journal-title":"Biomolecules"},{"key":"2025022408425833600_bib13","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"key":"2025022408425833600_bib14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/ndt\/gfv063","article-title":"Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases","volume":"30","author":"Papasotiriou","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025022408425833600_bib15","doi-asserted-by":"publisher","first-page":"e0170023","DOI":"10.1371\/journal.pone.0170023","article-title":"Development of a novel enzyme-linked immunosorbent assay targeting a neo-epitope generated by cathepsin-mediated turnover of type III collagen and its application in chronic obstructive pulmonary disease","volume":"12","author":"Rasmussen","year":"2017","journal-title":"PLoS One"},{"key":"2025022408425833600_bib16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","article-title":"A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen","volume":"43","author":"Barascuk","year":"2010","journal-title":"Clin Biochem"},{"key":"2025022408425833600_bib17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.34067\/KID.0001132021","article-title":"Collagen type III and VI remodeling biomarkers are associated with kidney fibrosis in lupus nephritis","volume":"2","author":"Genovese","year":"2021","journal-title":"Kidney360"},{"key":"2025022408425833600_bib18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/ckj\/sfz174","article-title":"Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients","volume":"14","author":"Genovese","year":"2020","journal-title":"Clin Kidney J"},{"key":"2025022408425833600_bib19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/ndt\/gfv301","article-title":"Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy","volume":"31","author":"Genovese","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025022408425833600_bib20","doi-asserted-by":"crossref","first-page":"e0283296","DOI":"10.1371\/journal.pone.0283296","article-title":"Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria","volume":"18","author":"Poulsen","year":"2023","journal-title":"PLoS One"},{"key":"2025022408425833600_bib21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.kint.2023.08.005","article-title":"A comprehensive description of kidney disease progression after acute kidney injury from a prospective, parallel-group cohort study","volume":"104","author":"Horne","year":"2023","journal-title":"Kidney Int"},{"key":"2025022408425833600_bib22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1681\/ASN.2015030309","article-title":"Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments","volume":"27","author":"Basile","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025022408425833600_bib23","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO 2012","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2025022408425833600_bib24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000368243","article-title":"The effects of acute kidney injury on long-term renal function and proteinuria in a general hospitalised population","volume":"128","author":"Horne","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2025022408425833600_bib25","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/ndt\/12.9.1883","article-title":"Urinary and serum type III collagen: markers of renal fibrosis","volume":"12","author":"Soylemezoglu","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2025022408425833600_bib26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.advms.2018.10.002","article-title":"Urinary procollagen III aminoterminal propeptide and \u03b2-catenin \u2013 new diagnostic biomarkers in solitary functioning kidney?","volume":"64","author":"Taranta-Janusz","year":"2019","journal-title":"Adv Med Sci"},{"key":"2025022408425833600_bib27","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/liv.15595","article-title":"Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease","volume":"43","author":"Johanse","year":"2023","journal-title":"Liver Int"},{"key":"2025022408425833600_bib28","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.jhepr.2023.100743","article-title":"PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease","volume":"5","author":"Nielsen","year":"2023","journal-title":"JHEP Rep"},{"key":"2025022408425833600_bib29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51394-4","article-title":"Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients","volume":"9","author":"Nielsen","year":"2019","journal-title":"Sci Rep"},{"key":"2025022408425833600_bib30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae413\/61230915\/sfae413.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/2\/sfae413\/61230915\/sfae413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/2\/sfae413\/61230915\/sfae413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:43:09Z","timestamp":1740386589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae413\/7928125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae413","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,18]]},"article-number":"sfae413"}}